CRISPR Therapeutics AG Contracts & Agreements

Employment Agreement, dated May 23, 2022, by and between CRISPR Therapeutics AG and Phuong Khanh Morrow (Filed With SEC on August 8, 2022)

Lease Commencement Date Agreement, dated May 1, 2022, by and between CRISPR Therapeutics AG and 105 W First Street Owner, L.L.C (Filed With SEC on August 8, 2022)

Description of Capital Shares (Filed With SEC on February 15, 2022)

Letter Agreement dated December 16, 2021 by and between CRISPR Therapeutics, Inc. and Pfizer Inc (Filed With SEC on February 15, 2022)

Letter Agreement dated January 6, 2022, by and between CRISPR Therapeutics, Inc. and 105 W First Street Owner, L.L.C (Filed With SEC on February 15, 2022)

Employment Agreement, dated October 14, 2021, by and between CRISPR Therapeutics, Inc. and Brendan Smith (Filed With SEC on October 14, 2021)

Second Amendment to Lease dated April __, 2021, by and between CRISPR Therapeutics, Inc. and 33 NYA OWNER (DE) LLC, as successor in interest to CRP/KING 33 NY AVE. OWNER, L.L.C (Filed With SEC on July 29, 2021)

Letter Agreement dated April 29, 2021 by and between CRISPR Therapeutics, Inc. and Pfizer Inc (Filed With SEC on July 29, 2021)

Lease, dated May 5, 2020, by and between CRISPR Therapeutics, Inc. and CRP/KING 33 NY AVE. OWNER, L.L.C (Filed With SEC on April 27, 2021)

First Amendment to Lease dated December 2, 2020, by and between CRISPR Therapeutics, Inc. and CRP/KING 33 NY AVE. OWNER, L.L.C (Filed With SEC on April 27, 2021)

First Amendment to the Strategic Collaboration and License Agreement dated March 17, 2021, between CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated (Filed With SEC on April 27, 2021)

Description of Capital Shares (Filed With SEC on February 16, 2021)

Lease, dated July 24, 2020, by and between the Registrant and 105 W First Street Owner, L.L.C (Filed With SEC on July 27, 2020)

Underwriting Agreement, dated as of June 30, 2020, among CRISPR Therapeutics AG and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Jefferies LLC, as representatives of the... (Filed With SEC on July 2, 2020)

Description of Capital Shares (Filed With SEC on February 12, 2020)

Amendment No. 1 to Research Collaboration Agreement by and between CRISPR Therapeutics AG and ViaCyte, Inc., dated as of April 30, 2019 (Filed With SEC on February 12, 2020)

Amendment No. 2 to Research Collaboration Agreement by and between CRISPR Therapeutics AG and ViaCyte, Inc., dated as of October 21, 2019 (Filed With SEC on February 12, 2020)

Joint Venture Termination Agreement, dated December 13, 2019, among Bayer Healthcare LLC (and certain affiliates of Bayer Healthcare LLC for purposes of Article II), CRISPR... (Filed With SEC on February 12, 2020)

Retirement Agreement, dated December 13, 2019, among Casebia Therapeutics Limited Liability Partnership, Bayer HealthCare LLC, CRISPR Therapeutics AG and CRISPR Therapeutics, Inc (Filed With SEC on February 12, 2020)

Option Agreement, dated December 13, 2019, between CRISPR Therapeutics AG and Bayer HealthCare LLC (Filed With SEC on February 12, 2020)

Assignment of Sublease and Sub-Sublease, dated December 13, 2019, between Casebia Therapeutics LLC and CRISPR Therapeutics, Inc (Filed With SEC on February 12, 2020)

Mandate Agreement, dated December 27, 2019, by and between CRISPR Therapeutics AG and Oriolus Consulting LLC (Filed With SEC on December 27, 2019)

Termination Agreement, dated December 27, 2019, by and between CRISPR Therapeutics AG and Rodger Novak (Filed With SEC on December 27, 2019)

Underwriting Agreement, dated as of November 20, 2019, among CRISPR Therapeutics AG and Goldman Sachs & Co. LLC, Piper Jaffray & Co. and Jefferies LLC, as representatives of the... (Filed With SEC on November 22, 2019)

Open Market Sale AgreementSM, dated August 30, 2019, by and between CRISPR Therapeutics AG and Jefferies LLC (Filed With SEC on August 30, 2019)

Amendment No. 2 to the Strategic Collaboration, Option and License Agreement by and between, on the one hand, Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals... (Filed With SEC on July 29, 2019)

Strategic Collaboration and License Agreement dated June 6, 2019, between CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated (Filed With SEC on July 29, 2019)

Underwriting Agreement, dated as of September 20, 2018, among CRISPR Therapeutics AG and Goldman Sachs & Co. LLC, Piper Jaffray & Co. and Barclays Capital Inc. as representatives... (Filed With SEC on September 21, 2018)

Open Market Sale AgreementSM, dated August 31, 2018, by and between CRISPR Therapeutics AG and Jefferies LLC (Filed With SEC on August 31, 2018)

Employment Agreement, dated November 13, 2017, by and between CRISPR Therapeutics, Inc. and Michael Tomsicek (Filed With SEC on March 8, 2018)

Employment Agreement, dated May 31, 2017, by and between CRISPR Therapeutics, Inc. and James R. Kasinger (Filed With SEC on March 8, 2018)

Employment Agreement, dated August 1, 2017, by and between CRISPR Therapeutics, Inc. and Tony Ho (Filed With SEC on March 8, 2018)

CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan (Filed With SEC on March 8, 2018)

Form of Incentive Stock Option Agreement under CRISPR Therapeutics AGs 2018 Stock Option and Incentive Plan (Filed With SEC on March 8, 2018)

Form of Non-Qualified Stock Option Agreement for Company Employees under CRISPR Therapeutics AGs 2018 Stock Option and Incentive Plan (Filed With SEC on March 8, 2018)

Form of Non-Qualified Stock Option Agreement for Non-Employee Directors under CRISPR Therapeutics AGs 2018 Stock Option and Incentive Plan (Filed With SEC on March 8, 2018)

Form of Restricted Stock Award Agreement under CRISPR Therapeutics AGs 2018 Stock Option and Incentive Plan (Filed With SEC on March 8, 2018)

Form of Restricted Stock Award Agreement for Company Employees under CRISPR Therapeutics AGs 2018 Stock Option and Incentive Plan (Filed With SEC on March 8, 2018)

Form of Restricted Stock Award Agreement for Non-Employee Directors under CRISPR Therapeutics AGs 2018 Stock Option and Incentive Plan (Filed With SEC on March 8, 2018)

Senior Executive Cash Incentive Bonus Plan (Filed With SEC on March 8, 2018)

Underwriting Agreement, dated as of January 4, 2018, among CRISPR Therapeutics AG and Goldman Sachs & Co. LLC, Piper Jaffray & Co. and Barclays Capital Inc., as representatives of... (Filed With SEC on January 5, 2018)

Advisory Agreement by and between CRISPR Therapeutics AG and Dr. Anthony Coles, dated as of December 20, 2017 (Filed With SEC on December 21, 2017)

Employment Agreement by and between CRISPR Therapeutics AG and Dr. Rodger Novak, dated as of December 20, 2017 (Filed With SEC on December 21, 2017)

Joint Development and Commercialization Agreement by and between, on the one hand, Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited, and on the... (Filed With SEC on December 18, 2017)

Amendment No. 1 to the Strategic Collaboration, Option and License Agreement by and between, on the one hand, Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals... (Filed With SEC on December 18, 2017)

Form of Incentive Stock Option Agreement under CRISPR Therapeutics AGs Amended and Restated 2016 Stock Option and Incentive Plan (Filed With SEC on November 8, 2017)

Form of Non-Qualified Stock Option Agreement for Company Employees under Registrants Amended and Restated 2016 Stock Option and Incentive Plan (Filed With SEC on November 8, 2017)

Form of Non-Qualified Stock Option Agreement for Non-Employee Directors under CRISPR Therapeutics AGs Amended and Restated 2016 Stock Option and Incentive Plan (Filed With SEC on November 8, 2017)

Form of Restricted Stock Award Agreement under CRISPR Therapeutics AGs Amended and Restated 2016 Stock Option and Incentive Plan (Filed With SEC on November 8, 2017)

Form of Restricted Stock Award Agreement for Company Employees under Registrants Amended and Restated 2016 Stock Option and Incentive Plan (Filed With SEC on November 8, 2017)

Form of Restricted Stock Award Agreement for Non-Employee Directors under CRISPR Therapeutics AGs Amended and Restated 2016 Stock Option and Incentive Plan (Filed With SEC on November 8, 2017)

Second Amended and Restated Employment Agreement, dated October 2, 2017, by and between CRISPR Therapeutics, Inc. and Samarth Kulkarni (Filed With SEC on October 2, 2017)

CRISPR THERAPEUTICS AG AMENDED AND RESTATED 2016 STOCK OPTION AND INCENTIVE PLAN (Filed With SEC on June 2, 2017)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on May 4, 2017)

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEENFILED WITH THE SECURITIES AND EXCHANGE... (Filed With SEC on December 16, 2016)

CRISPR THERAPEUTICS AG Common Shares (nominal value CHF 0.03 per share) Underwriting Agreement (Filed With SEC on October 7, 2016)

SUBSCRIPTION AGREEMENT (Filed With SEC on September 9, 2016)

REGISTRATION RIGHTS AGREEMENT made as of June 10, 2016 by andamong (Filed With SEC on September 9, 2016)

CRISPR THERAPEUTICS AG 2015 STOCK OPTION AND GRANT PLAN (Filed With SEC on September 9, 2016)

CRISPR THERAPEUTICS AG 2016 STOCK OPTION AND INCENTIVE PLAN1 (Filed With SEC on September 9, 2016)

CRISPR THERAPEUTICS AG 2016 EMPLOYEE STOCK PURCHASE PLAN1 (Filed With SEC on September 9, 2016)

CONSENT TO SUBLEASE (Filed With SEC on September 9, 2016)

Category

Industry

Companies

Contracts

CRISPR Therapeutics AG Contracts & Agreements